Evotec SE, a life science company focused on accelerating drug discovery and development, announced that it has received a US$ 25 million milestone payment from Bristol Myers Squibb following scientific progress achieved under their ongoing strategic neuroscience collaboration. The payment will support continued research and development within the partnership’s joint pipeline of programs addressing neurodegenerative diseases.
Long-Term Partnership Focused on Disease-Modifying Treatments
The partnership between Evotec and Bristol Myers Squibb was established in 2016 with the aim of discovering and developing disease-modifying therapies for neurodegenerative conditions, where treatment options remain limited.
Over the years, the collaboration has yielded a robust pipeline of innovative programs, including EVT8683—in-licensed by Bristol Myers Squibb in 2021 and now known as BMS-986419—which has successfully completed Phase 1 clinical trials.
Reflecting the partners’ sustained progress and shared scientific goals, the collaboration was extended in 2023 for an additional eight years.
Scientific Leadership Perspective
“Patients living with neurodegenerative conditions urgently need therapies that go beyond symptom management,” said Dr. Cord Dohrmann, Chief Scientific Officer at Evotec. “This achievement deepens our collaboration with Bristol Myers Squibb. Together, we are translating emerging disease biology into therapeutic opportunities to deliver meaningful options for patients.”
About the Companies
Evotec SE is a global life science company pioneering the future of drug discovery and development. By integrating breakthrough science, AI-driven innovation, and advanced technologies, Evotec accelerates the journey from concept to cure with enhanced speed and precision.
Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases across therapeutic areas including oncology, immunology, and neuroscience.
